Australian Phase 3 biotech developing VEGF inhibitors for wet AMD.
Industry: Health Care
First Day Return: -8.9%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 09/24/2020 |
Offer Price | $13.50 |
Price Range $13.50 - $13.50 | |
Offer Shares (mm) | 9.5 |
Deal Size ($mm) | $128 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 10/16/2020 |
Offer Price | IPO Intelligence Only |
Price Range | IPO Intelligence Only |
Offer Shares (mm) | IPO Intelligence Only |
Deal Size ($mm) | $128 |
Lock-Up Date | IPO Intelligence Only |
Street Research | IPO Intelligence Only |
Underwriters |
---|
IPO Intelligence Only |
Company Data | |
---|---|
Headquarters | South Yarra, Australia |
Founded | 1984 |
Employees at IPO | 8 |
Website www.opthea.com |